Cargando…

Penicillin in oral aphthosis, new insight for an old drug: A randomized, double-blind, controlled clinical trial

BACKGROUND: Oral aphthosis is a painful ulceration of mucus membranes characterized by round or oval lesions with central necrosis and erythematous haloes. Due to unknown etiology, treatment is highly controversial and based mainly on individual experience. The aim of this study was to investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Owlia, Mohammad Bagher, Mirzadeh, Mahboobeh, Mehrpoor, Golbarg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698373/
https://www.ncbi.nlm.nih.gov/pubmed/33273940
http://dx.doi.org/10.4103/jrms.JRMS_748_19
_version_ 1783615815458750464
author Owlia, Mohammad Bagher
Mirzadeh, Mahboobeh
Mehrpoor, Golbarg
author_facet Owlia, Mohammad Bagher
Mirzadeh, Mahboobeh
Mehrpoor, Golbarg
author_sort Owlia, Mohammad Bagher
collection PubMed
description BACKGROUND: Oral aphthosis is a painful ulceration of mucus membranes characterized by round or oval lesions with central necrosis and erythematous haloes. Due to unknown etiology, treatment is highly controversial and based mainly on individual experience. The aim of this study was to investigate the safety and efficacy of topical penicillin 6.3.3 for the treatment of recurrent aphthous stomatitis. MATERIALS AND METHODS: This randomized, double-blind, controlled clinical trial was done in Shahid Sadoughi Hospital Clinic in Yazd (2011–2012). Fifty patients aged 15–45 with recurrent oral aphthosis were randomly divided into two groups. After obtaining informed consents, patients in the case and control groups were treated (four times/day for a week), respectively, by topical penicillin 6.3.3 powder and placebo in similar vial. The patients who had acute-onset oral aphthae (≤48 h of appearance) with diameter ≥5 mm were included. History of sensitivity to β-lactam antibiotics and cephalosporin; spontaneous recovery during <5 days in previous episodes; concurrent systemic, infectious, or any autoimmune disorders; history of taking drugs (local or systemic) from 2 weeks prior to presentation; alcohol or drug abuse; smoking cigarette or tobacco; and poor compliance were exclusion criteria. Patients were examined in days 0, 3, 6, and 8. The main outcome measure was reduction in the median pain. Burning, pain, erythema, and inflammation were recorded as complications. RESULTS: Of 25 patients receiving penicillin, 13 were female and 12 were male. Regarding the pain score (mean difference = 1.6 vs. 0.88, P = 0.012) and size of aphthus (mean difference = 9.43 vs. 1.24, P = 0.008), patients who received penicillin had significantly better results than the placebo group on day 8 after the treatment. The mean duration to healing was 3 days for penicillin group and 6 days for placebo group (P = 0.016). No topical or systemic adverse effects were observed. CONCLUSION: Our study showed a dramatic response to topical penicillin with respect to placebo. Hence, it seems that penicillin could be a safe and effective option in managing oral aphthosis.
format Online
Article
Text
id pubmed-7698373
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-76983732020-12-02 Penicillin in oral aphthosis, new insight for an old drug: A randomized, double-blind, controlled clinical trial Owlia, Mohammad Bagher Mirzadeh, Mahboobeh Mehrpoor, Golbarg J Res Med Sci Original Article BACKGROUND: Oral aphthosis is a painful ulceration of mucus membranes characterized by round or oval lesions with central necrosis and erythematous haloes. Due to unknown etiology, treatment is highly controversial and based mainly on individual experience. The aim of this study was to investigate the safety and efficacy of topical penicillin 6.3.3 for the treatment of recurrent aphthous stomatitis. MATERIALS AND METHODS: This randomized, double-blind, controlled clinical trial was done in Shahid Sadoughi Hospital Clinic in Yazd (2011–2012). Fifty patients aged 15–45 with recurrent oral aphthosis were randomly divided into two groups. After obtaining informed consents, patients in the case and control groups were treated (four times/day for a week), respectively, by topical penicillin 6.3.3 powder and placebo in similar vial. The patients who had acute-onset oral aphthae (≤48 h of appearance) with diameter ≥5 mm were included. History of sensitivity to β-lactam antibiotics and cephalosporin; spontaneous recovery during <5 days in previous episodes; concurrent systemic, infectious, or any autoimmune disorders; history of taking drugs (local or systemic) from 2 weeks prior to presentation; alcohol or drug abuse; smoking cigarette or tobacco; and poor compliance were exclusion criteria. Patients were examined in days 0, 3, 6, and 8. The main outcome measure was reduction in the median pain. Burning, pain, erythema, and inflammation were recorded as complications. RESULTS: Of 25 patients receiving penicillin, 13 were female and 12 were male. Regarding the pain score (mean difference = 1.6 vs. 0.88, P = 0.012) and size of aphthus (mean difference = 9.43 vs. 1.24, P = 0.008), patients who received penicillin had significantly better results than the placebo group on day 8 after the treatment. The mean duration to healing was 3 days for penicillin group and 6 days for placebo group (P = 0.016). No topical or systemic adverse effects were observed. CONCLUSION: Our study showed a dramatic response to topical penicillin with respect to placebo. Hence, it seems that penicillin could be a safe and effective option in managing oral aphthosis. Wolters Kluwer - Medknow 2020-10-28 /pmc/articles/PMC7698373/ /pubmed/33273940 http://dx.doi.org/10.4103/jrms.JRMS_748_19 Text en Copyright: © 2020 Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Owlia, Mohammad Bagher
Mirzadeh, Mahboobeh
Mehrpoor, Golbarg
Penicillin in oral aphthosis, new insight for an old drug: A randomized, double-blind, controlled clinical trial
title Penicillin in oral aphthosis, new insight for an old drug: A randomized, double-blind, controlled clinical trial
title_full Penicillin in oral aphthosis, new insight for an old drug: A randomized, double-blind, controlled clinical trial
title_fullStr Penicillin in oral aphthosis, new insight for an old drug: A randomized, double-blind, controlled clinical trial
title_full_unstemmed Penicillin in oral aphthosis, new insight for an old drug: A randomized, double-blind, controlled clinical trial
title_short Penicillin in oral aphthosis, new insight for an old drug: A randomized, double-blind, controlled clinical trial
title_sort penicillin in oral aphthosis, new insight for an old drug: a randomized, double-blind, controlled clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698373/
https://www.ncbi.nlm.nih.gov/pubmed/33273940
http://dx.doi.org/10.4103/jrms.JRMS_748_19
work_keys_str_mv AT owliamohammadbagher penicillininoralaphthosisnewinsightforanolddrugarandomizeddoubleblindcontrolledclinicaltrial
AT mirzadehmahboobeh penicillininoralaphthosisnewinsightforanolddrugarandomizeddoubleblindcontrolledclinicaltrial
AT mehrpoorgolbarg penicillininoralaphthosisnewinsightforanolddrugarandomizeddoubleblindcontrolledclinicaltrial